Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • neuroendocrine tumours

    - PMLiVE

    Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

    The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

    - PMLiVE

    Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn

    The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials

    - PMLiVE

    MHRA marks 100 years of patient safety through biological standards

    The UK regulator highlights its century-long role in establishing safety and consistency benchmarks

    - PMLiVE

    MHRA and FDA expand collaboration on AI and medtech regulation

    National Commission on the Regulation of AI in Healthcare brings together UK and US experts

    - PMLiVE

    Ipsen’s tumour treatment receives MHRA marketing authorisation

    This is the first approval in the UK for previously treated advanced neuroendocrine tumours

    - PMLiVE

    New National Commission launched to strengthen AI regulation

    The Commission will unite healthcare leaders, regulators and technology experts to shape future AI governance

    - PMLiVE

    UK’s first new type of antibiotic for UTIs in nearly 30 years approved by MHRA

    The oral pill is effective against many drug-resistant infections, including E. coli

    - PMLiVE

    Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours

    Treatment options following disease progression have previously been limited for many patients

    - PMLiVE

    Roche’s Evrysdi tablets approved by MHRA to treat spinal muscular atrophy

    It is hoped the new formulation will offer patients greater freedom and flexibility compared to the liquid version

    Biogen Idec building

    Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease

    Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease

    - PMLiVE

    AbbVie’s Elahere granted MHRA approval to treat platinum-resistant ovarian cancer

    Approximately 7,500 people are diagnosed with ovarian cancer every year in the UK

    - PMLiVE

    Alnylam’s Amvuttra approved by MHRA to treat rare heart disease ATTR-CM

    The drug has been authorised to treat both wild-type and hereditary forms of the disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links